SAN FRANCISCO, Dec. 12 /PRNewswire/ -- To help life sciences companies across the Pacific form strategic partnerships, Burrill & Company, together with CapitalBio Corporation, WuXi PharmaTech Co. Ltd., ChipScreen BioSciences Ltd., Shenzhen City Government, BayHelix Group and other co-sponsors, are presenting The China Life Sciences Partnering Forums in three most advanced cities in China.
-- Beijing on January 16, 2006 -- Shanghai on January 18, 2006 -- Shenzhen on January 20, 2006
The Forums will be focused on the bio-partnering opportunities between Chinese and Western companies. The discussion topics include: How to “bridge” across the Pacific? What are the opportunities and challenges in Greater China? What are Western companies looking for in Chinese partners? What are Chinese companies looking for in Western partners? Top executives from IBM Healthcare and Life Sciences Group, Deloitte, Amgen, Roche, Eli Lilly, GSK, Pfizer, Perkins Coie, Heller Ehrman, Epitomics, BioMarker, Excel and Baxter will speak at the Forums.
“This event is the first of its kind organized by Burrill & Company in China,” explained G. Steven Burrill, CEO of Burrill & Company, a San Francisco based global leader in life sciences with principal activities in Venture Capital, Merchant Banking and Media. “We have invited world-class speakers from business, academia and government on both sides of the Pacific.”
“By bringing together Western life sciences executives and a large number of Chinese leaders and relevant governmental officials, the Forums will serve as a powerful platform to ‘bridge’ the life science industries in Greater China and the Western world and will lead to significant strategic partnerships shaping the entire industry,” said Jonathan Wang, General Manager for Great China at Burrill & Company.
For more information, please visit event website at www.burrillandco.com/burrill/china_forums.
About Burrill & Company
Founded in 1994, Burrill & Company is a 50 person San Francisco-based global leader in Life Sciences Venture Capital, Merchant Banking and Media. It has over $500 million of venture capital funds under management and has completed over $1.5 billion of merchant banking transactions. With a vision of China becoming an important global pharmaceutical development and manufacturing center, Burrill & Company has established Burrill Greater China Group (BGCG) to “bridge” the life science industries in Greater China and the Western world.
About CapitalBio Corporation
CapitalBio Corporation, headquartered in Beijing, is a distinguished life science company that develops and commercializes a wild range of products, which cover fields from life science research to bio-safety tests, clinical diagnostics and drug discovery. The company was recently named “Red Herring 100 Companies in Asia.”
About WuXi Pharma Tech Co. Ltd.
WuXi PharmaTech Co., Ltd. is a leader in China’s emerging and fast-growing pharmaceutical R&D services industry. The Shanghai-based company provides services to support new drug discovery and drug development. It engages chemistry research, from lead discovery, optimization and development to commercial manufacturing. After winning the 9th place in the Deloitte Technology Fast 500 Asia Pacific 2004 Annual Competition, the company was recently named “Red Herring 100 Companies in Asia.”
About ChipScreen BioSciences Ltd.
ChipScreen BioSciences Ltd., is a leading drug discovery company specialized in small molecule therapeutics of transcription modulators for metabolic diseases, cancer, and chronic immune/inflammatory diseases.
About the BayHelix Group
The BayHelix Group is a non-profit, invitation-only organization for business leaders of Chinese origin in life sciences and healthcare. BayHelix has approximately 230 members throughout the United States, Canada and Greater China. 28% of the members are “C-level” executives in life sciences companies.
Burrill & Company
CONTACT: Jeff Miller of Burrill & Company, +1-415-591-5476, orJMiller@b-c.com
Web site: http://www.burrillandco.com/
